BioCentury | Jul 8, 1996
Company News

Oncor, Boston University School of Medicine deal

...ONC's OncorPharm affiliate acquired an option for an exclusive worldwide right to develop pharmaceuticals based on...
...the skin pigment melanin and the production of p53 protein, which helps suppress abnormal growth. OncorPharm...
BioCentury | Apr 1, 1996
Company News

Oncor, Johns Hopkins University School of Medicine deal

...ONC's OncorPharm subsidiary acquired an exclusive worldwide license to diagnostic and therapeutic applications of a highly...
...pressure and arterial blockage. ONC plans to develop diagnostics to identify people with the mutation. OncorPharm...
BioCentury | Feb 12, 1996
Company News

Oncor, Yale University School of Medicine other research news

...raise the question whether naturally occurring triple helixes are a source of genetic instabilty. ONC's OncorPharm Inc....
BioCentury | Jun 12, 1995
Clinical News

Oncor regulatory update

...which has a worldwide license to the patent, has sublicensed the therapeutic rights to its OncorPharm...
...develop genetic testing products from the technology and to provide other companies with limited sublicenses. OncorPharm...
BioCentury | Apr 24, 1995
Company News

Oncor news

...financing through a $3 million private placement (see page B9). Oncor Inc. (ONCR) ONCR formed OncorPharm Inc....
Items per page:
1 - 5 of 5
BioCentury | Jul 8, 1996
Company News

Oncor, Boston University School of Medicine deal

...ONC's OncorPharm affiliate acquired an option for an exclusive worldwide right to develop pharmaceuticals based on...
...the skin pigment melanin and the production of p53 protein, which helps suppress abnormal growth. OncorPharm...
BioCentury | Apr 1, 1996
Company News

Oncor, Johns Hopkins University School of Medicine deal

...ONC's OncorPharm subsidiary acquired an exclusive worldwide license to diagnostic and therapeutic applications of a highly...
...pressure and arterial blockage. ONC plans to develop diagnostics to identify people with the mutation. OncorPharm...
BioCentury | Feb 12, 1996
Company News

Oncor, Yale University School of Medicine other research news

...raise the question whether naturally occurring triple helixes are a source of genetic instabilty. ONC's OncorPharm Inc....
BioCentury | Jun 12, 1995
Clinical News

Oncor regulatory update

...which has a worldwide license to the patent, has sublicensed the therapeutic rights to its OncorPharm...
...develop genetic testing products from the technology and to provide other companies with limited sublicenses. OncorPharm...
BioCentury | Apr 24, 1995
Company News

Oncor news

...financing through a $3 million private placement (see page B9). Oncor Inc. (ONCR) ONCR formed OncorPharm Inc....
Items per page:
1 - 5 of 5